NYSE:AZN
Astrazeneca PLC Stock News
$67.75
-0.510 (-0.747%)
At Close: Mar 28, 2024
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years
09:08am, Thursday, 28'th Mar 2024
Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.
AstraZeneca CEO Soriot on Pharmaceuticals in China
09:27pm, Tuesday, 26'th Mar 2024
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sideline
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
06:56pm, Tuesday, 26'th Mar 2024
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
11:01am, Tuesday, 26'th Mar 2024
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
03:41pm, Wednesday, 20'th Mar 2024
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
12:51pm, Wednesday, 20'th Mar 2024
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
01:00am, Wednesday, 20'th Mar 2024
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
06:56pm, Tuesday, 19'th Mar 2024
Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
02:51pm, Tuesday, 19'th Mar 2024
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Biotech Stock Soars on AstraZeneca Buyout
10:50am, Tuesday, 19'th Mar 2024
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.
AstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it getting
08:51am, Tuesday, 19'th Mar 2024
AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in t
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
03:45am, Tuesday, 19'th Mar 2024
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma in $2.4bln deal
03:34am, Tuesday, 19'th Mar 2024
AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126% premium to Nasdaq-listed Fusion'
AstraZeneca to buy Fusion Pharma for $2 billion in cash
03:11am, Tuesday, 19'th Mar 2024
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.